Aladdin Healthcare SE said it has gained approval from OTC Markets Group Inc to have the company’s shares quoted on the OTCQB market under the symbol ALDNF, moving up from its current OTC Pink Market listing.
Along with the new US stock quotation, Aladdin Healthcare is re-positioning its business through merger or acquisition opportunities to transform its commercial viability and in turn monetise its AI and blockchain technologies.
In a statement, Wade Menpes-Smith, Aladdin Healthcare CEO said: “By adding this US quote, we are now moving into the world’s best capital market for healthcare technology, whilst executing our global strategy to attract investment from North American based investors. ALDNF will provide Aladdin with access to a larger community for further strategic transactions.
“As a leading developer of AI healthcare diagnostics and drug discovery applications for age-related diseases, we see it as a great opportunity to present our business model and its growth prospects to investors who are attracted to innovative companies with rapid growth potential.”
READ: Aladdin Healthcare Technologies begins trading of shares on Pink Open Market
The company said its intention is to control its entire supply chain through owning its own healthcare network, which will consist of doctors, patients and their data.
To build something of significance the company is looking to develop one of the largest blockchain-driven healthcare patient networks in Asia (ex-China) and is targeting 100 million patients on its network over the medium term.
Aladdin Healthcare said it is actively identifying targets and aims to announce its first acquisition in the months ahead.
After its first acquisition, the company will then be in a position to distribute its variety of proprietary blood tests, coronavirus (COVID-19) tests and other AI-driven diagnostics in stages to millions of users within its network.
As the ecosystem grows Aladdin Healthcare will introduce a multitude of other third-party tests and applications that will drive revenue and growth, culminating in billions of valuable medical data inputs for multiple diseases, thereby opening up significant opportunity for the global pharmaceutical industry to collaborate with the company.
In parallel, Aladdin through its OTC quote will seek to revalue its business and aim to raise capital in the US to support its acquisitions and working capital.
Aladdin Healthcare Technologies (OTCQB:ALDNF, ETR:NMI) SE, and its wholly-owned subsidiary Aladdin Healthcare Technologies (OTCQB:ALDNF, ETR:NMI) Ltd, is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early-stage disease diagnosis and the end-to-end drug discovery process.
Aladdin targets aged-related disease including a significant focus on Alzheimer’s disease and accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to gather targeted data including confidentially and securely, genome, tabular, MRI, PET, cognition and other lifestyle data.
These datasets are then analyzed by its award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose aged, related diseases. This new diagnostic process will save significant time and costs for healthcare professionals.
Additionally, Aladdin’s AI drug discovery platform will be used by pharmaceutical companies to speed up drug development, clinical trials and predict outcomes more accurately.
Contact the author at jon.hopkins@proactiveinvestors.com